Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
No serious or treatment related adverse events in either the first or second cohort Second cohort demonstrated an average 60% reduction in Dysphasia Likert score and an average 80% reduction… Read More

